- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Schick reports 1998 financial results
Digital imaging firm Schick Technologies this month reported a big jump in revenues as the firm's products begin to hit the market. For the year (end-March), Schick posted revenues of $38.5 million, up 139% compared with $16.1 million the year before.
Digital imaging firm Schick Technologies this month reported a big jump in revenues as the firm's products begin to hit the market. For the year (end-March), Schick posted revenues of $38.5 million, up 139% compared with $16.1 million the year before. The company had net income for the year of $2.4 million, compared with a net loss of $352,000 in 1997. The 1998 figures include a one-time patent litigation settlement of $600,000.
Schick reported that sales of its accuDEXA bone densitometer are going well. In addition, the Long Island City, NY, company reported that it received 510(k) clearance from the Food and Drug Administration for an additional application for accuDEXA: use of the system to help physicians determine the risk of fracture. AccuDEXA received its initial 510(k) market clearance in December for assessing bone mineral density (SCAN 4/15/98).
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
